Loading asset research
PepGen Inc. Common Stock
PEPGNasdaq · USD · StocksQuote as of · Exchange session not verified$2.98
-1.16%
Today
PEPG
Loading 1D prices…
Market cap
$206.1M
Volume
683K
52w high
$7.8052w low
$1.31Company profile
PepGen Inc. Common Stock
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Boston, MA, United States
Employees
57
Fiscal year end
1231
CIK
1835597
Session & valuation
Open$3.03
Previous close$3.02
Day high$3.10
Day low$2.95
30-day avg. volume953.2K
Outstanding shares69.3M
Diluted EPS-$2.12
Latest annual period
P/E (trailing)-1.41
P/E (forward)-2.87
Price / book1.72
Beta1.97
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| MSLESatellos Bioscience Inc. Common Stock | $206.9M | $0.00 | — | -$1.70 | +1.49% | Buy |
| ANTXAN2 Therapeutics Inc. Common Stock | $204.2M | $0.00 | — | -$1.16 | -4.92% | Buy |
| DERMJourney Medical Corporation Common Stock | $204.1M | $61.2M | -18.67% | -$0.47 | +2.12% | Buy |
| NKTXNkarta Inc. Common Stock | $208.4M | $0.00 | — | -$1.41 | +3.56% | Buy |
| TNXPTonix Pharmaceuticals Holding Corp. Common Stock | $203.6M | $13.1M | -946.22% | -$14.57 | -3.34% | Buy |